Genezen Healthcare

Genezen is a specialized cell and gene therapy contract development and manufacturing organization (CDMO) focused on viral vector production. The company provides end-to-end services for the development and manufacture of lentiviral (LVV), retroviral (RVV), and adeno-associated viral (AAV) vectors, supporting programs from preclinical research through to commercial supply. Genezen operates a state-of-the-art cGMP facility in Fishers, Indiana, and recently expanded its footprint by acquiring a commercial-scale manufacturing site in Lexington, Massachusetts, from uniQure. This acquisition enables Genezen to support the global production of gene therapies, including the first FDA-approved gene therapy for hemophilia B. The company is a key partner for leading biotech firms and academic institutions, leveraging deep expertise in vector biology and process intensification.